| Antioxidant treatment may protect pancreatic beta cells through the attenuation of islet fibrosis in an animal model of type 2 diabetes. | |
| | |
MedLine Citation:
|
PMID: 21971557 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Islet fibrosis could be important in the progression of pancreatic beta cell failure in type 2 diabetes. It is known that oxidative stress is involved in the pancreatic fibrosis through the activation of pancreatic stellate cells. However, no study has investigated the in vivo effects of antioxidants on islet fibrogenesis in type 2 diabetes. In this study, antioxidants (taurine or tempol) were administered in drinking water to Otsuka Long-Evans Tokushima Fatty rats, an animal model of type 2 diabetes, for 16weeks. An intraperitoneal glucose tolerance test revealed that the blood glucose levels after the glucose injection were decreased by the antioxidants. The insulin secretion after the glucose injection, which was markedly reduced in the rats, was also restored by the antioxidants. Beta cell mass and pancreatic insulin content were greater in the rats treated with the antioxidants than in the untreated rats. Beta cell apoptosis was attenuated in the rats by the antioxidants. Finally, islet fibrosis and the activation of pancreatic stellate cells were markedly diminished in the rats by the antioxidants. Our data suggest that antioxidants may protect beta cells through the attenuation of both islet fibrosis and beta cell apoptosis in type 2 diabetes. |
| | |
Authors:
|
Esder Lee; Gyeong Ryul Ryu; Seung-Hyun Ko; Yu-Bae Ahn; Kun-Ho Yoon; Hunjoo Ha; Ki-Ho Song |
Related Documents
:
|
7124287 - Metabolic studies in women with previous gestational diabetes during contraceptive trea... 9580307 - Serum ferritin as a component of the insulin resistance syndrome. 12664077 - The metabolic syndrome is associated with elevated circulating c-reactive protein in he... 9165227 - High density lipoprotein apolipoprotein ai kinetics in niddm: a stable isotope study. 11590287 - Clinical and aetiological profile of early onset diabetes mellitus: data from a tertiar... 17109677 - Rimonabant: endocannabinoid inhibition for the metabolic syndrome. |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-9-24 |
Journal Detail:
|
Title: Biochemical and biophysical research communications Volume: - ISSN: 1090-2104 ISO Abbreviation: - Publication Date: 2011 Sep |
Date Detail:
|
Created Date: 2011-10-5 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0372516 Medline TA: Biochem Biophys Res Commun Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011. Published by Elsevier Inc. |
Affiliation:
|
Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Temporal assessment of ribose treatment on self-assembled articular cartilage constructs.
Next Document: Mesenchymal stem cell like (MSCl) cells generated from human embryonic stem cells support pluripoten...